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Background: Impetigo is caused by both Streptococcus pyogenes and Staphylococcus aureus; the relative contributions
of each have been reported to fluctuate with time and region. While S. aureus is reportedly on the increase in most
industrialised settings, S. pyogenes is still thought to drive impetigo in endemic, tropical regions. However, few studies
have utilised high quality microbiological culture methods to confirm this assumption. We report the prevalence and
antimicrobial resistance of impetigo pathogens recovered in a randomised, controlled trial of impetigo treatment
conducted in remote Indigenous communities of northern Australia.
Methods: Each child had one or two sores, and the anterior nares, swabbed. All swabs were transported in skim milk
tryptone glucose glycogen broth and frozen at –70°C, until plated on horse blood agar. S. aureus and S. pyogenes were
confirmed with latex agglutination.
Results: From 508 children, we collected 872 swabs of sores and 504 swabs from the anterior nares prior to
commencement of antibiotic therapy. S. pyogenes and S. aureus were identified together in 503/872 (58%) of sores;
with an additional 207/872 (24%) sores having S. pyogenes and 81/872 (9%) S. aureus, in isolation. Skin sore swabs taken
during episodes with a concurrent diagnosis of scabies were more likely to culture S. pyogenes (OR 2.2, 95% CI 1.1 – 4.4,
p = 0.03). Eighteen percent of children had nasal carriage of skin pathogens. There was no association between the
presence of S. aureus in the nose and skin. Methicillin-resistance was detected in 15% of children who cultured S. aureus
from either a sore or their nose. There was no association found between the severity of impetigo and the detection of
a skin pathogen.
Conclusions: S. pyogenes remains the principal pathogen in tropical impetigo; the relatively high contribution of S.
aureus as a co-pathogen has also been confirmed. Children with scabies were more likely to have S. pyogenes detected.
While clearance of S. pyogenes is the key determinant of treatment efficacy, co-infection with S. aureus warrants
consideration of treatment options that are effective against both pathogens where impetigo is severe and prevalent.
Trial registration: This trial is registered; ACTRN12609000858291.
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Impetigo is an epidermal infection caused by Staphylococ-
cus aureus and Streptococcus pyogenes. It is common in
Indigenous children of northern Australia, with preva-
lence as high as 70% [1]. The reported relative abundance
of S. aureus and S. pyogenes has varied over time [2]. In re-
cent decades, S. aureus and increasingly methicillin-
resistant S. aureus (MRSA) has been the dominant re-
ported pathogen in impetigo studies worldwide, most of
which have taken place in temperate-climate regions, usu-
ally in affluent countries [3] where there is a low burden
of disease. By contrast, in tropical regions, impetigo is far
more common, and carries the greatest burden of se-
quelae [4]. S. pyogenes is assumed to have remained the
dominant pathogen [5] but some reports are emerging
on skin and soft tissue infections caused by S. aureus
[6,7]. There is limited microbiological surveillance of
causative impetigo pathogens from high burden con-
texts and rates of antimicrobial resistance are often un-
known [5]. Impetigo is strongly associated with scabies
infestation in tropical environments [8], but the influence
of scabies on the microbiology of impetigo has not previ-
ously been described. We report here on the microbiology
of impetigo in a high burden setting, and explore the asso-
ciations of this microbiology with age, sex, region, severity,
presence of scabies and nasal carriage of skin pathogens.
Our dataset derives from a large, non-inferiority rando-
mised controlled trial (RCT) comparing trimethoprim-
sulphamethoxazole (SXT) with benzathine penicillin G
(BPG) for the treatment of impetigo in Indigenous chil-
dren [9].
Methods
Study design
Indigenous children aged 3 months to 13 years were
participants in the RCT. Children were eligible to par-
ticipate on more than one occasion if at least 90 days
had elapsed since their last involvement. As such, 508
children from 12 remote communities of the Northern
Territory were enrolled for 663 episodes of impetigo;
all analysis presented here has been restricted to a
child’s first episode only. Six communities (comprising
463/508 children) were located in the tropical climatic
region, commonly referred to as the “Top End”. The
remaining communities were in Central Australia where a
desert climate prevails. Children were stratified by im-
petigo severity. The severe stratum included children
with ≥2 purulent or crusted sores and ≥5 overall body
sores.
Swabbing, transportation and culture methods
Each child had swabs taken from one or two sores (ac-
cording to whether the episode was classified as mild or
severe) prior to commencing antibiotics. A swab of theanterior nares was obtained to determine carriage of im-
petigo pathogens in the context of infection. Swabs were
collected between 26 November 2009 and 20 November
2012. Rayon tipped cotton swabs (Copan, Italy) were
transported at 4°C in 1 mL of skim milk tryptone glu-
cose glycogen broth (STGGB) and frozen at −70°C
within 5 days of collection. Swabs were defrosted, vor-
texed and an aliquot plated on horse blood agar and in-
cubated for 48 hours at 37°C [10]. S. aureus and S.
pyogenes were identified morphologically and confirmed
with latex agglutination. All S. aureus isolates were sta-
phytect (Oxoid, UK) and deoxyribonuclease (DNase, BD
Diagnostics, USA) positive. S. pyogenes agglutinated with
group A Lancefield antisera (Oxoid).Antimicrobial susceptibility testing
Antimicrobial susceptibility testing for S. aureus was
determined on the Vitek2 platform using 22359 VITEK
AST-P612 cards (bioMerieux, France) with Clinical and
Laboratory and Standards Institute (CLSI, 2011) break-
points utilised [11]. MRSA was defined as any S. aureus
with a positive cefoxitin screen. Non-multidrug resist-
ant MRSA (nmMRSA) was defined as MRSA resistant
to <3 additional non beta-lactam antibiotics [12].
Multidrug-resistant MRSA (mMRSA) was defined as
MRSA that was resistant to ≥3 non beta-lactam antibi-
otics [12].
We performed susceptibility testing for S. pyogenes
with penicillin, erythromycin and clindamycin discs
using CLSI disc diffusion standards. SXT susceptibility
for S. pyogenes was determined with an E test® (bioMerieux)
according to the European committee on antimicrobial sus-
ceptibility testing (EUCAST) standards (www.eucast.org,
last accessed 15 November 2014). SXT susceptible
strains had a MIC ≤1 mg/L and resistant isolates had a
MIC >2 mg/L.
Ethics statement
This study was approved by the Northern Territory
Department of Health and Menzies School of Health
Research Human Research Ethics Committee (09/08).
Written informed consent was obtained from a child’s
parent or guardian for all study procedures.Statistical analysis
Mixed-effects logistic regression (random effects ac-
counting for correlated data due to multiple sores for
the children in the severe impetigo strata) using Stata 13
(Statacorp, Texas, USA) was performed to assess associ-
ations between the growth of skin pathogens and the
presence of scabies, severe impetigo, age, sex, region and
nasal carriage.
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Baseline microbiology results
Sores
We obtained 872 swabs of sores from 508 children with
untreated impetigo (median age 7 years, interquartile
range [IQR] 5 – 9 years) at baseline. Seventy-two per-
cent of children were in the severe impetigo stratum, all
of whom had two sores swabbed. An impetigo pathogen
was identified in 488/508 (96%) of children. From the
872 sores swabbed, S. aureus and S. pyogenes were iden-
tified together in 503/872 (58%), S. pyogenes alone in
207/872 (24%), and S. aureus alone in 81/872 (9%) of
sores. Swabs from children in the severe impetigo
stratum were not more likely to detect one or both skin
pathogens compared with swabs from children in the
mild impetigo stratum (Table 1). S. aureus was less likely
to be detected in older children (OR 0.6, 95% CI 0.4 –
0.9 for children ≥ 5 years, Wald test on 2 degrees of free-
dom p = 0.04) or in children from Central Australia (OR
0.5, 95% CI 0.3 – 0.9, p = 0.02). Children from Central
Australia were less likely to have sores co-infected with
both S. aureus and S. pyogenes than children from the
Top End (OR 0.5, 95% CI 0.3 – 0.9, p = 0.01).
Scabies
Scabies was diagnosed at baseline in 84/508 (17%) of
children: by age group: 0-4 years (28/136, 21%); 5 –
9 years (40/271, 15%) and 10 – 13 years (16/101, 16%).
Those with scabies present were more likely to also
have S. pyogenes detected from sores (OR 2.2, 95% CI
1.1 – 4.4, p = 0.03) (Table 1).
Other beta haemolytic streptococci
Seven hundred and fifty-four beta haemolytic strepto-
cocci were cultured from skin and nose swabs of 508
children with impetigo. Of these, 740/754 (98%) were
S. pyogenes with 710 from skin swabs and 30 from
the nose swabs. The remaining beta haemolytic
streptococci were group C (2 skin, 2 nose) and group
G (7 skin, 3 nose).Table 1 Results from logistic regression models to assess asso
severity, presence of scabies and region
Variable S. pyogenes in sores S. aureus in sores Both S. au
OR 95% CI OR 95% CI OR
Female 1.3 0.8 – 2.1 1.0 0.7 – 1.4 1.1
0-4 years 1 (ref) 1 (ref) 1
5-9 years 1.1 0.7 – 2.0 0.6 0.4 – 0.9 0.8
10 – 13 years 1.2 0.6 – 2.4 0.5 0.3 – 0.9 0.7
Severe strata 1.4 0.8 – 2.6 0.7 0.4 – 1.1 1.1
Scabies present 2.2 1.1 – 4.4 0.8 0.5 – 1.3 0.9
Central Australia 1.2 0.5 – 2.8 0.5 0.3 – 0.9 0.5Antibiotic susceptibility
One isolate each of S. pyogenes and S. aureus were se-
lected per child for reporting of the antibiotic suscepti-
bility profile. Where possible, isolates cultured from skin
sores were selected, with the remainder coming from
swabs of the anterior nares.
S. pyogenes
There were 455 children with at least one S. pyogenes
isolate available for antibiotic susceptibility assessment.
All S. pyogenes isolates were susceptible to penicillin and
erythromycin. Clindamycin resistance was detected in 9/
455 (2%) S. pyogenes isolates. SXT resistance was detected
in 4/455 (<1%) isolates at baseline with a MIC >2 mg/L.
[13] The median SXT MIC for S. pyogenes was 0.094
(interquartile range, 0.094 – 0.125) mg/L.
S. aureus
There were 435 children with at least one S. aureus
isolate available for antibiotic susceptibility assessment.
Methicillin-resistance in S. aureus was detected in 65/
435 (15%) isolates, all of which were nmMRSA. There
was no detection of mMRSA. The respective resistance
rates for other antibiotics by child were penicillin 413/
435 (95%), SXT 3/435 (<1%), erythromycin 60/435
(14%) and fusidic acid 9/435 (2%). Inducible clindamy-
cin resistance was reported in 60/435 (14%), 86% of
which were MSSA. All 3 SXT resistant isolates were
nmMRSA. Other antibiotics included on the VITEK
card for S. aureus susceptibility testing all had resistance
rates below 0.02%. For those with S. aureus detected,
the presence of MRSA did not reach significance for
sex, age group, severe strata, the presence of scabies or
region (Table 1).Nasal carriage of skin pathogens
S. aureus
A nasal swab was taken at baseline for 504/508 (99%) of
children. Before treatment, 91/504 (18%) children hadciations between impetigo pathogens and age, sex,
reus and S. pyogenes in sores MRSA in sores positive for S. aureus
95% CI OR 95% CI
0.8 – 1.5 1.0 0.6 – 1.7
(ref) 1 (ref)
0.5 – 1.1 0.9 0.5 – 1.6
0.4 – 1.2 0.7 0.3 – 1.5
0.7 – 1.7 0.6 0.3 – 1.1
0.6 – 1.4 1.4 0.7 – 2.6
0.3 – 0.9 1.1 0.4 – 2.7
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nares. Both S. aureus and S. pyogenes were recovered
from 16/91 (18%), S. pyogenes alone from 14/91 (15%)
and S. aureus alone from 61/91 (67%). Of children with
nasal carriage of S. aureus, 66/77 (86%) had MSSA and
11/77 (14%), MRSA. Nasal carriage of S. aureus and
S. pyogenes was respectively 77/504 (15%) and 30/504 (6%).
We investigated the association of nasal carriage of
S. aureus and the presence of S. aureus in impetigo le-
sions. There were 504 children with both skin and nose
swabs available (Table 2). Surprisingly, of the 410 chil-
dren culturing S. aureus on the skin, only 54 (13%) also
harboured S. aureus in the nose. Based on the antibio-
gram, of the 54 with S. aureus in both the nose and skin
sores, four had discordant S. aureus strains (i.e., MSSA
at one site and MRSA at the other). Of the 94 children
without S. aureus on the skin, there were 23 (24%)
children who harboured S. aureus in the nose. Of 424
children harbouring S. pyogenes on the skin, 28 (7%) had
concurrent growth of S. pyogenes from the anterior
nares. There were 2 children with isolated growth of
S. pyogenes from the anterior nares. Extending a model
of Table 2, nasal colonisation with S. aureus was associ-
ated with less, not more, S. aureus on the skin (OR 0.6,
95% CI 0.4 – 1.0, p = 0.04), suggesting a separate
epidemiology of S. aureus at these two sites.
Discussion
S. pyogenes remains the key impetigo pathogen in Indi-
genous children of remote Australia. Co-infection with
S. aureus is also highly prevalent. In addition, our study
extends understanding of the microbiology of impetigo
where scabies is endemic. Where scabies is present, we
found that S. pyogenes is more likely to be recovered
from impetigo lesions. We also found no positive correl-
ation between nasal carriage of S. aureus and recovery of
S. aureus from impetigo lesions, and no association be-
tween the severity of impetigo and recovery of either S.
pyogenes, S. aureus or both.
The stronger association of S. pyogenes (than
S. aureus) with scabies presence concurs with earlier
work that linked scabies outbreaks with subsequentTable 2 Identification of Staphylococcus aureus from any
impetigo lesion and the anterior nares for all children
with at least one skin and nose swab available (n = 504
children)
Anterior nares Total
Positive Negative
Impetigo At least one
sore positive
54 (13%) 356 (87%) 410 (100%)
Negative 23 (24%) 71 (76%) 94 (100%)
Total 77 (15%) 427 (85%) 504 (100%)epidemics of post-streptococcal glomerulonephritis
[14] and recommended treatment of scabies at a
community level to reduce the complications of
streptococcal pyoderma [15,16]. Scabies association
with impetigo in urban Indigenous children was
similarly high to that found in our study at a rate of
25/111 (23%) [17]. No prior studies have reported
on the association between scabies and MRSA de-
tection. While the rates of both were high, we were
unable to detect a significant association between
these.
Both S. pyogenes and S. aureus have been reported as
key impetigo pathogens, however the reported relative
contributions of each have fluctuated over time and re-
gion. Previous microbiology studies of impetigo in both
urban and remote Australian Indigenous children have
shown high rates of co-infection [17,18]. Valery et al. de-
tected co-infection with skin pathogens in 54% of urban
Indigenous children. Of those children who had both
impetigo and scabies, S. pyogenes was recovered from
82% and S. aureus from 77% [17]. S. pyogenes remains
an important skin pathogen in our region, as has also
been reported from Fiji [8,19] and supports the ongoing
prescription of antibiotics active against S. pyogenes for
the effective treatment of impetigo in tropical regions.
Results of our clinical trial confirmed the importance of
clearing S. pyogenes in order to achieve healing of impe-
tigo lesions [9].
The isolated dominance of S. aureus and rising rates
of MRSA reported elsewhere in skin and soft tissue
infections [6,20,21] were not found in our study.
Methicillin-resistance was detected in 15% of S. aureus
isolates. This is lower than previously reported for our
remote tropical context [22] and lower than recent
rates found in a 20 year survey of S. aureus in our re-
gion [23] but consistent with a study of impetigo in
urban Indigenous children of northern Australia [17].
We were uncertain whether MRSA varies by age, as this
had not previously been explored, but we found no evi-
dence that it does. The observation that MRSA rates
were stable across age groups, suggests early colonisa-
tion of children in remote communities with MRSA
strains.
We found that children in the severe strata, who had
more than five purulent or crusted sores, were not more
likely than children in the mild strata, to be infected
with S. pyogenes and/or S. aureus. Although those strati-
fied as mild, indicating fewer overall sores, may have had
a less severe phenotype for each individual sore, the
microbiology of these sores was no different. We thus
provide robust evidence to refute earlier observational
data in patients with impetigo where the association of
co-infection with a more severe phenotype was sus-
pected but not confirmed [24,25].
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ported and is not thought to be the reservoir for skin in-
fection, the anterior nares are thought to only rarely
harbor S. pyogenes [26]. As such, throat swabs were not
included in our study design as we focused on the
characterization of nasal carriage of S. aureus. However,
our findings of nasal carriage of S. pyogenes in 7% of
children provide external validation of results from mili-
tary recruits where nasal carriage of S. pyogenes was
found in 8% of those with ecthyma [27]. There was no
correlation between S. aureus nasal carriage and the re-
covery of S. aureus from impetigo lesions. Previous stud-
ies have concluded that when impetigo predominantly
affects the lower limbs, there is either an absence of S.
aureus nasal carriage or a different genotype [28]. Our
data supports this observation in that 67% of impetigo
episodes involved only the lower limbs [9]. As has pre-
viously been shown in military recruits [29], nasal
decolonization is also unlikely to be a useful strategy in
reducing the burden of impetigo in our tropical, en-
demic setting.
One study from Ghana in the 1970s with a similar
tropical climate found impetigo to be dominated by
Lancefield groups C and G streptococci [30]. These
findings were not reproduced in our study and have not
been confirmed in other published microbiology studies
from our region [18] or other tropical contexts [31].
Non-group A streptococci do not appear to play a sig-
nificant role in the pathogenesis of impetigo.
A strength of this study is the standardization of
procedures for screening, swabbing and microbiological
culture in the context of a clinical trial conducted ac-
cording to International Conference on Harmonisation
Good Clinical Practice guidelines. In addition, the large
number of children recruited from 12 distinct communi-
ties from two regions of the Northern Territory suggests
that the conclusions are rigorous. Genotypic assessment
of the isolates was not conducted to determine the cor-
relation of skin and nose isolates. The inability to correl-
ate the molecular epidemiology with the phenotype is a
limitation of this study. While the cost of molecular typ-
ing overall has become more affordable, the large num-
ber of isolates in this study made further molecular
analysis cost prohibitive.
Conclusions
S. pyogenes remains a key pathogen in impetigo in trop-
ical contexts, despite the rise in S. aureus found in many
industrialised and tropical settings. Our findings are in
keeping with those reported from Fiji [8] and confirm
that impetigo in tropical contexts continues to be driven
by S. pyogenes. In the absence of local microbiology for
impetigo, treatment algorithms should remain focussed
on the treatment of S. pyogenes. However, we havedemonstrated that co-infection with both S. pyogenes
and S. aureus is likely. As such, consideration of treat-
ment of impetigo with an agent that is effective against
both S. pyogenes and S. aureus is important. We have
also concluded that in the context of impetigo, there is
no association between nasal colonisation and skin in-
fection with S. aureus.
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